NCT02760797View on ClinicalTrials.gov

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

April 6, 2018

Study Completion Date

April 6, 2018

Conditions
Neoplasms
Interventions
DRUG

Emactuzumab

Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.

DRUG

RO7009789

RO7009789 will be administered IV every 3 weeks (every cycle).

Trial Locations (6)

1200

Cliniques Universitaires St-Luc, Brussels

19104

University Pennsylvania Hospital, Philadelphia

31059

Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse

69373

Centre Leon Berard; Departement Oncologie Medicale, Lyon

94805

Institut Gustave Roussy; Sitep, Villejuif

Unknown

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02760797 - A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter